tudy: Axicabtagene Ciloleucel in Refractory Large B-cell Lymphoma
3 Dec, 2018 | 23:41h | UTCCommentary: ASH 2018: More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial – eCancer News (free)